Correct antibiotic dosing could preserve lung microbial diversity in cystic fibrosis

WASHINGTON – Children and young adults with cystic fibrosis (CF) whose lung infections were treated with suboptimal doses of antibiotics had fewer changes in lung microbial diversity during the IV treatment, and their microbial diversity levels were higher 30 days later, a multi-institutional study that includes Children’s researchers shows. By contrast, patients who were treated with therapeutic doses had greater decreases in lung microbial diversity and significantly lower diversity levels when the antibiotic treatment ended as well as 30 days later.

“With the subtherapeutic treatment group, this could represent a ‘basement effect’ where it is harder to decrease diversity when it is already low to start. Also patients in the subtherapeutic group had more advanced disease than those in the therapeutic group, which may influence the findings,” explains Andrea Hahn, M.D., M.S., an infectious disease specialist at Children’s National Health System and the study’s lead author.

The findings, published online Feb. 22, 2019, in Scientific Reports, clearly establish the importance of the interplay between baseline microbial diversity and lung function and have the potential to improve clinical practices, the research team writes.

More than 30,000 people in the U.S. live with CF, a genetic disease that leads to recurrent lung infections that gradually deplete lung function over time. People with this disease frequently require hospitalization for these infections, known as acute pulmonary exacerbations (APEs), which are typically treated with antibiotics. These often include beta-lactams, a class of antibiotics that include penicillin and a host of other structurally related compounds.

Worsening lung function in CF patients has been linked to decreased microbial diversity in their lungs, a factor thought to be caused by repeated dosing of antibiotics to treat APEs. Although it’s well known that patients frequently don’t achieve therapeutic doses of antibiotics that effectively clear their infections, it’s been unclear how microbial diversity changes in patients who receive subtherapeutic doses compared with patients who receive therapeutic doses.

To investigate this question, Dr. Hahn and colleagues recruited 20 patients between 1 to 21 years of age who were treated for APEs with beta-lactam antibiotics at Children’s National. For each patient, the researchers collected four samples of respiratory fluid:

• When study participants were well
• While they were having an APE
• Right after their antibiotic course ended and
• Again at least 30 days later.

They ran each sample through genetic testing to determine the types of bacteria present and their relative abundance. The research team also collected blood samples from each patient while they underwent their antibiotic courses, as well as data on their lung function.

These 20 patients underwent 31 courses of antibiotics over the study period, which lasted from March 2015 to August 2016. Dr. Hahn and colleagues found that only about 45 percent of these courses were considered therapeutic, with blood concentrations of these drugs rising high enough to effectively treat their infections.

Dr. Hahn and colleagues suspect that patients who often don’t achieve therapeutic blood levels of antibiotics may be genetically predisposed to metabolize beta-lactam antibiotics quickly. Repeated subtherapeutic courses of antibiotics could significantly knock down microbial diversity without effectively clearing infections, leading to more lung damage that negatively impacts lung function over time.

Dr. Hahn adds that eventually it may be possible to avoid this effect by keeping closer tabs on CF patients’ antibiotic blood levels in real time to make sure that each APE is treated with therapeutic-level dosing.

“What this study shows is that levels of the antibiotics we give probably play a role in patients’ ability to recover baseline diversity,” she says. “If we pay more attention to drug levels when using these types of antibiotics to ensure that dosing is sufficient, we could potentially improve patients’ clinical outcomes over time.”

In addition to Dr. Hahn, study co-authors include Hani Fanous, Hollis Chaney, M.D., pulmonologist, Iman Sami, M.D., pulmonologist, Geovanny F. Perez, M.D., pulmonologist and co-director of the Severe Asthma Clinic, Anastassios C. Koumbourlis, M.D., chief of the Division of Pulmonary and Sleep Medicine and director of the Cystic Fibrosis Center, James E. Bost, Ph.D., research division chief of biostatistics and study methodology, John N. van den Anker, M.D., Ph.D., division chief of Clinical Pharmacology, and Robert J. Freishtat, M.D., M.P.H., senior investigator in the Center for Genetic Medicine Research, all of Children’s National; Caroline Jensen and Senior Author Keith A. Crandall, The George Washington University; Stan Louie, University of Southern California; and Edith T. Zemanick, University of Colorado Anschutz Medical Campus.

Financial support for the research described in the report was provided by the National Institutes of Health under K12 Career Development award K12HL119994 and the NIH National Center for Advancing Translational Sciences’ Second Annual President’s Award for Innovative Research under award UL1TR000075. The researchers’ findings are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Media contact: Diedtra Henderson | 443-610-9826 | 202-476-4500